Jason Zemansky’s rating is based on a nuanced analysis of ... Market dominance by competitors like Merck and recent clinical disappointments have raised questions about dom’s potential to be a profit ...

Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its ...

Le-Vel, the world leader in premium nutrition and lifestyle products, has generously donated approximately 64,000 of its meal ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive ...

Most of the rise in Treasury yields is due to U.S. economic data coming in stronger than anticipated, with the unemployment rate actually falling while inflation has been stubbornly resilient. The ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans ...

Jason joined Channel 9 Eyewitness News in 2006. For seven years, Jason reported on Charlotte-Mecklenburg government issues before being promoted to the Action 9 consumer investigator role in 2013.

Oppenheimer Asset Management highlights eight stocks in Health Care and Consumer Staples sectors poised for short positions amid S&P 500 highs.

The Fund seeks to provide an above-average level of current income and reasonable long-term capital appreciation. It invests in common stocks of mid-size and large companies whose stocks typically ...